Safety of coagulation factor concentrates

Area of Science:

• Hematology
• Biotechnology
• Virology

Background:

• Early plasma-derived concentrates had adverse effects.
• Increased purity of concentrates ameliorated some effects but introduced new risks.
• These risks include inhibitor formation and pathogen transmission due to altered immunogenicity and large plasma pools.

Purpose of the Study:

• To evaluate strategies for minimizing risks associated with clotting factor concentrates.
• To compare plasma-derived concentrates with recombinant clotting factors.
• To discuss the safety of coagulation factor concentrates in light of pathogen transmission and inhibitor formation.

Main Methods:

• Review of strategies for improving purity and safety of clotting factor concentrates.
• Discussion of viral reduction techniques, including donor screening and physical/inactivation methods.
• Consideration of recombinant clotting factor production and theoretical risks.

Main Results:

• Increased purity of plasma-derived concentrates reduced some adverse effects but heightened risks of inhibitors and pathogen transmission.
• Recombinant clotting factors, while produced without plasma, carry theoretical pathogen transmission risks.
• Current safety measures include donor screening, viral reduction, and active immunization for specific pathogens.

Conclusions:

• Optimizing the safety of coagulation factor concentrates requires a multi-faceted approach.
• Continued surveillance and active immunization are critical for managing blood-borne pathogen risks.
• The safety of prion removal from concentrates remains an area for further investigation.